Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29144989 | 0.96 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL18386447 | 0.86 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL18697460 | 0.86 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL25650764 | 0.86 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL11162517 | 0.83 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL9295522 | 0.77 | — | — | |
| SCHEMBL31518161 | 0.77 | — | — | |
| SCHEMBL8542060 | 0.77 | — | — | |
| SCHEMBL1025624 | 0.77 | — | — | |
| SCHEMBL6673550 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-8153625-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-26 | — | — | US | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| EP-3992176-B1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596555-A1 | ABHD6 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-0769498-A1 | Sulfonamide derivatives with elastase inhibiting activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-04-23 | — | — | EP | disclosed |
| EP-0761680-A2 | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0757984-A1 | Hydroxamic acid derivatives useful for inhibiting gelatinase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0717736-A4 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LTD (HK) | 1996-08-28 | — | — | EP | disclosed |
| EP-0717736-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007269-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | ALDH1A1 571/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | ALDH1A1 764/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | ALDH1A1 548/4885 |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | ALDH1A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.